Figure 3
DN Pmel-1 mediate tumor regression without IL2 and gp100 25-33 /DC support. Mice bearing subcutaneous B16 tumors were myeloablated and given BM support prior to receiving adoptive transfer of 106 mock or DN Pmel-1. Subsequently, mice received IL2 or gp10025-33/DC support, both, or neither. Even without IL2 and gp10025-33/DC support, DN Pmel-1 mounted robust anti-tumor activity, repressing B16 tumor outgrowth up to 90 days post tumor implantation (3A). Support with IL2, gp10025-33/DC, or both lead to better tumor protection, however, DN Pmel-1 still demonstrate superior anti-tumor activity compared to mock Pmel-1 (3B, 3 C, 3D). E: Kaplan-Meier survival plot of mice treated as described above.